We anticipate 5% of patients will be lost to follow up given the results of pilot study.
We asked the epidemiologists about four topics: Research context: aim, persons who give the assignment, financiers, collaborative partners, research method; Main outcomes of the research, considered important by epidemiologists; Follow up given to the results; Explanation of this follows up.
Resolving this question in humans is self-evidently difficult in terms of pathological assessment despite advances in MR based imaging and definitive clinical evaluation requires many years of follow up given the temporal evolution of disease progression.
Applying the 2010 criteria cumulatively over 5 years follow up gave an estimated IR of 48/100 000; for the 1987 criteria this was 44/100 000.
This study was conducted on 729 normotensive singleton pregnant women who had referred for prenatal visit and on follow up gave birth to healthy term newborns.
Two hundred and four patients were included at baseline with 143 (63 female and 80 male) having had radiographs of both knees taken at baseline and 12 year follow up, giving a follow up rate of 78%.
Across developing country cohorts, 6% had died by 12 months and 12% had been lost to follow-up giving a combined 18% dead and lost to follow-up which is 37% higher than in Khayelitsha [ 1].
This should be an interesting follow-up, given how many of other Marvel franchises have progressed over the years.
Patients with MGUS and SMM require indefinite follow-up given their lifelong risk of progression to MM or related malignancy [32].
